Dr. Kaplan's Revolutionary Death Ray for Kids

The image of a child undergoing modern anticancer treatments is especially jarring—little bald-headed androgynous rascals, so cherubic you can't help but marvel at the cruelty of a world that permits gangly tumors to spread through such innocence, and the heart bleeds at the thought of poisonous chemotherapy wreaking its havoc on their growing bodies.

St. Jude's Children's Hospital has become especially skilled at showcasing such patients in ads to attract donation dollars, but when it comes to matching innocence with the terrifying barbarism of modern anticancer imagery, nobody can hold a candle to little Gordon Isaacs and the 6-million volt Death Ray looming behind him:

Stark images like this can speak a thousand words, but how many of them are true? While the picture speaks of hopeless overkill, of Cold War weaponry, of Lovercraft-like horrors, the reality—at least as goes this pic—is none of these things.

Rather, the photo (taken at Stanford University Hospital in 1957 and now in the public domain) illustrates the first American patient treated with the now-standard linear accelerator (radiotherapy) for retinoblastoma. That patient happened to be little Gordy, and he'd already lost his right eye to the cancer, and a localized tumor was threatening the vision in his left. Instead of putting Gordo under the knife for yet another surgery, his doctor, the great Henry Kaplan, decided to try the accelerator.

The result was a success. Gordon retained the vision in his left eye and as of 1984, the last word I can reliably find for him, he was a healthy adult male with good vision in one eye living somewhere in the vicinity of the San Francisco Bay Area. Kaplan's name still carries massive weight in Hodgkin's circles, and rightfully so—before Henry Kaplan, people diagnosed with Hodgkin's Lymphoma were considered lost causes. Today they're often told (appropriately or not) that they're lucky because it's a curable cancer, thanks in great part to Kaplan's pioneering and innovative work.

By Ross Bonander
Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap